| |
|
| |
News |
|
The let-7 microRNA reduces tumor growth in mouse models of lung cancer.
Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ.
MicroRNAs have been increasingly implicated in human cancer and interest has grown about the potential to use microRNAs to combat cancer. Lung cancer is the most prevalent form of cancer worldwide and lacks effective therapies. Here we have used both in vitro and in vivo approaches to show that the let-7 microRNA directly represses cancer growth in the lung. We find that let-7 inhibits the growth of multiple human lung cancer cell lines in culture, as well as the growth of lung cancer cell xenografts in immunodeficient mice. Using an established orthotopic mouse lung cancer model, we show that intranasal let-7 administration reduces tumor formation in vivo in the lungs of animals expressing a G12D activating mutation for the K-ras oncogene. These findings provide direct evidence that let-7 acts as a tumor suppressor gene in the lung and indicate that this miRNA may be useful as a novel therapeutic agent in lung cancer.
Go to: PubMed
|
|
BIOO, Among Others, Meets With NIH on Expanding Use of RNAi Technology
Representatives of a dozen RNAi reagent and tool companies attended the one-day meeting to provide an overview of their core technologies to members of a committee charged with making recommendations to the NIH’s scientific directors on how best to improve access to RNAi technologies.
Go to: RNAi News
|
Nature Magazine Showcases BIOO Scientific Corp.
BIOO Scientific's in vivo delivery agent, MaxSuppressor™ in vivo RNA LANCEr (cat. 3407) was showcased in the September 13th 2007 issue of Nature (Vol 449 Issue no. 7159). The product was featured on the siRNA-Product focus page directly following page 252. BIOOۥs in vivo delivery agent is publicized along with products from companies such as Qiagen, Sigma Aldrich and Integrated DNA technologies. MaxSuppressor™ in vivo RNA LANCEr in vivo delivery agent has been shown to be effective in reducing gene expression in a number of target tissues. For more information about MaxSuppressor™ in vivo RNA-LANCEr delivery agent please contact us at techsupport3@biooscientific.com. |
|
|
BIOO Sponsors the Feodor Lynen Lecturer
BIOO Scientific sponsors the Feodor Lynen Lecturer, Susan Gottesman from NIH, speaking on Sunday morning, February 3, 2008, as the opening lecture at the Miami Winter Symposium. Dr. Ford will be the Chairperson for that session and present the Lynen Medal Award to Dr. Gottesman after her talk.
Please go to www.miami.edu/mws for details.
|
BIOO Scientific Receives an NIH Grant for Improving Antibody Technology
BIOO was awarded a grant from the National Institute of Allergy and Infectious Disease to fund research titled "Engineered Polypeptides for Improved Antibody Production". This grant will utilize our significant expertise in antibody and protein manufacturing to efficiently produce antibodies that are more specific than traditional antibodies.
|
NSF Funds BIOO Research Project
The U.S. National Science Foundation announces the funding for Bioo Scientific's research project titled "Improved In Vivo Delivery of SiRNA." |
| |
|
| |
Bioo Scientific Corp., 3913 Todd Lane Suite 312
Austin, TX 78744, USA - Phone: (512) 707-8993 © Copyright 2008 |
|
|
|
